MARIETTA, Ga., May 4, 2011 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane, announced today the launch of AmnioFix™ Nerve Wrap, the Company's latest biologic implant processed to offer surgical and healing options for nerve repair.
Produced from the MiMedx Group's proprietary Purion® process, AmnioFix™ Nerve Wrap is an allograft from amniotic tissue that is utilized for various nerve repair surgical procedures. Parker H. "Pete" Petit, Chairman and CEO, said, "AmnioFix™ Nerve Wrap is another minimally manipulated tissue offering created by our proprietary Purion® process that was developed by Surgical Biologics, a wholly-owned subsidiary of MiMedx that we acquired in January 2011."
For use as an in vivo nerve wrap in peripheral nerve trauma, AmnioFix™ Nerve Wrap provides a protective barrier and contributes to the three phases of the natural healing process. . . inflammatory phase, proliferation phase and remodeling phase.
John Daniel, President and Founder of Surgical Biologics, stated "We are very excited to be pioneering another application for processed amniotic tissue. Ophthalmology was the industry's initial application for processed amniotic tissue. Surgical Biologics is the first and leading company specifically founded to promote the use of amniotic membrane in multiple surgical applications beyond ophthalmology. In addition to our new nerve wrap offering, Surgical Biologics has pioneered amniotic tissue uses in applications such as diabetic wound care, spinal surgery, orthopedics, burns, trauma and others."
Surgical Biologics has been supplying amniotic tissue for over five years with a stellar record of quality and safety. In addition to the MiMedx branded AmnioFix™ and EpiFix™ tissue, Surgical Biologics is also the leading supplier of amniotic tissue to distributors, having supplied over 30,000 implants to date. Included in the list of distributors to which Surgical Biologics supplies amniotic tissue are AFCell Medical, Alphatec Spine, BioArthro, NuShield, NuTech Medical, IOP Ophthalmics and Snoasis Medical.
Petit added, "Since its founding over five years ago, Surgical Biologics has made ground breaking advances in the use of amniotic membrane in new and innovative ways, and has clearly been the industry leader. The launch of AmnioFix™ Nerve Wrap is not only another example of their innovative approach; it is also an example of the caliber of new offerings that are resulting from the combination of Surgical Biologics with MiMedx."
About the Company
MiMedx is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants manufactured from human amniotic membrane. The Company has an experienced team poised to capitalize on its science and technology to generate rapid sales growth and profitability. Our mantra is "Repair, don't replace" because our biochemists, engineers, designers and physicians believe it is better to augment repair when possible rather than replace traumatized, but otherwise healthy tissues and structures. Our platform technologies, HydroFix™ and CollaFix™, and our newest platform technology, Purion® developed by our wholly-owned subsidiary, Surgical Biologics, have a vast number of potential applications in treating traumatized tissue and structures and MiMedx is focused on commercializing multiple applications for the Company's three technology platforms. In parallel, we are seeking strategic relationships, in selective categories, to more rapidly commercialize our technologies.
SOURCE MiMedx Group, Inc.